

Therapy History (10 of 24)

Therapy	Regimen	Start Date	Stop Date	Days	Refill	Cost
1	ddl, d4T, NFV	2	2	2	15	\$33.88
2	ddl, d4T, EFV	5	5	9	9	\$28.44
3	ddl, NFV, EFV	5	5	16	16	\$38.50
4	d4T, NFV, EFV	5	5	14	14	\$40.24
5	ddl, NFV, EFV	5	7	15	15	\$38.77
6	ddl, d4T, EFV	5	7	8	8	\$28.71

See More... [See More] [Full Screen] [Evaluation]

Therapy Regimen Evaluated

3TC, d4T, NVP

III THERAPY REJECTED III

This therapy was rejected for the following reason(s) Additional information about the therapy is provided but this therapy is NOT advisable

- Viramune (nevirapine/NVP) Resistance Advisory: According to the last genotype data entered, the patient's virus currently has mutation(s) which is/are associated with resistance to Viramune. FilMauE, RejectionS4
- Resistance Advisory: According to the last genotype data entered, the patient's virus currently has the following mutations, M184V [RT]. The genotype test displays evidence of the M184V/M184I mutation which is associated with resistance to 3TC. However, this mutant has increased sensitivity to the antiretroviral activity of AZT and ADV so an AZT/3TC or AZT/ADV combination is still useable. Therefore combinations which contain AZT/3TC and AZT/ADV are shown as therapy options although these therapies have been ranked down +5 in favor of three drug combinations with no resistant mutants, FilMauB, RejectionS1
- Efavirenz and Viramune Resistance Advisory: The patient's last phenotypic assay demonstrates phenotypic resistance to Efavirenz and Viramune, therefore, therapies containing Efavirenz and Viramune are not recommended at this time. FilResC, RejectionS2

Fig. 128

CAUTION YELLOW ALERT CAUTION

W3

- NVPΔ: Drug Interaction Alert: Patient is currently taking rifabutin and there is insufficient data to assess whether dose adjustments are necessary. These drugs